BioCentury
ARTICLE | Clinical News

Glyxambi empagliflozin/linagliptin regulatory update

September 26, 2016 7:00 AM UTC

EMA’s CHMP recommended approval of Glyxambi empagliflozin/linagliptin from Boehringer and Eli Lilly to treat Type II diabetes. The companies expect approval of the product by the European Commission i...